123 related articles for article (PubMed ID: 34345424)
1. Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan.
Peces R; Mena R; Peces C; Cuesta E; Lapunzina P; Selgas R; Nevado J
Clin Kidney J; 2021 Aug; 14(8):1987-1989. PubMed ID: 34345424
[No Abstract] [Full Text] [Related]
2. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
[TBL] [Abstract][Full Text] [Related]
3. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
4. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
[TBL] [Abstract][Full Text] [Related]
5. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
Hines CB; Hooper GL; Collins-Yoder A
Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
[TBL] [Abstract][Full Text] [Related]
6. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.
Gilbert RD; Evans H; Olalekan K; Nagra A; Haq MR; Griffiths M
Pediatr Nephrol; 2017 May; 32(5):893-896. PubMed ID: 28194574
[TBL] [Abstract][Full Text] [Related]
9. Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.
Kai H; Shinozaki Y; Nishikubo A; Watanabe M; Tawara T; Iwase M; Tsunoda R; Moriyama N; Usui T; Kawamura T; Nagai K; Hagiwara M; Saito C; Morito N; Usui J; Yamagata K
CEN Case Rep; 2016 May; 5(1):87-90. PubMed ID: 28509176
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE; Gansevoort RT;
Am J Kidney Dis; 2017 Feb; 69(2):210-219. PubMed ID: 27856088
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.
Shoaf SE; Chapman AB; Torres VE; Ouyang J; Czerwiec FS
J Clin Pharmacol; 2017 Jul; 57(7):906-917. PubMed ID: 28218410
[TBL] [Abstract][Full Text] [Related]
12. Review of tolvaptan for autosomal dominant polycystic kidney disease.
Baur BP; Meaney CJ
Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
[TBL] [Abstract][Full Text] [Related]
13. An update on tolvaptan for autosomal dominant polycystic kidney disease.
Poch E; Rodas L; Blasco M; Molina A; Quintana L
Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Watkins PB; Lewis JH; Kaplowitz N; Alpers DH; Blais JD; Smotzer DM; Krasa H; Ouyang J; Torres VE; Czerwiec FS; Zimmer CA
Drug Saf; 2015 Nov; 38(11):1103-13. PubMed ID: 26188764
[TBL] [Abstract][Full Text] [Related]
15. Effect of tolvaptan in a patient with autosomal dominant polycystic kidney disease after living donor liver transplantation.
Uchiyama K; Honda K; Yoshida R; Kamijo Y; Yanagi M; Nakatsuka M; Ishibashi Y
CEN Case Rep; 2016 Nov; 5(2):227-231. PubMed ID: 28508983
[TBL] [Abstract][Full Text] [Related]
16. Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report.
Pellegrino AM; Annicchiarico Petruzzelli L; Riccio E; Pisani A
BMC Nephrol; 2019 Nov; 20(1):426. PubMed ID: 31752750
[TBL] [Abstract][Full Text] [Related]
17. Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea.
Kim HY; Lee SJ; Kim BK; Kim M; Bae EH; Ma SK; Kim SW
Electrolyte Blood Press; 2018 Dec; 16(2):23-26. PubMed ID: 30899311
[TBL] [Abstract][Full Text] [Related]
18. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
Torres VE
Nephrol Dial Transplant; 2019 Jan; 34(1):30-34. PubMed ID: 30312438
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
20. Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report.
Kunizawa K; Hoshino J; Mizuno H; Suwabe T; Sumida K; Kawada M; Yamanouchi M; Sekine A; Hayami N; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Shibata S; Ubara Y
Case Rep Nephrol Dial; 2018; 8(1):62-69. PubMed ID: 29692992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
